Taihua plc, an investment holding company, develops, manufactures, distributes, and sells traditional Chinese medicine (TCM) products and active pharmaceutical ingredients (APIs) in the People’s Republic of China. The company operates in four segments: Paclitaxel, Homoharringtonine, TCM Products, and Forsythia. Its APIs products include paclitaxel, which is extracted from the bark of the yew tree for the treatment of ovaries, breast, lungs, skin, and mucous membranes cancer; and Homoharringtonine, an alkaloid extracted from branches and leaves of the cephalotaxus tree for the treatment of acute myeloid leukaemia and other cancers. The company also offers TCM products, including gengnianan tablet, duzhong pingya tablet, zaoren anshen keli, bunao anshen tablet, jiangzi jianfei tablet, dabaidu capsule, runing tablet, and bian tong pian. In addition, it cultivates, harvests, and sells Forsythia, a flowering shrub for use as the basis of TCM preparations. Taihua plc is based in Xi'an, the People's Republic of China.
taihua plc (TAIH:London Stock Exchange)
No. 16 Zhong Hua
Room 201, Unit 3
239 KeJi Road, Hi-tech Zone
Phone: 86 29 8832 6501
Fax: 86 29 8832 6502www.taihplc.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for TAIH.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact TAIHUA PLC, please visit www.taihplc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.